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Identity 




HACE1 was first cloned by sequencing clones obtained 
from a fetal brain cDNA library, and was designated as 
KIAA1320 (Nagase et al., 2000).  
The cDNA encodes a 909 amino acid protein 
(GenBank: NM_020771.3). 
Description 
The HACE1 gene is located on chromosome 6 
(105175968-105307794); 24 exons. 
Protein 
Description 
Human HACE1 encodes HACE1 protein, which 
containing 909 amino acid residues (size ~103 kDa) 
(Anglesio et al., 2004). HACE1 possesses six N-
terminal ankyrin repeats (amino acid: 64-93; 97-126; 
130-159; 163-192; 196-227; 228-257) and a C-terminal 
HECT domain (amino acid: 572-909; active cysteine 
residue at position 876). 
Expression 
Anglesio et al. showed that a 4,6-kb transcript of 
HACE1 with strong expression in heart, brain, 
placenta, pancreas, as well as adult and fetal kidney. 
HACE1 expression is virtually undetectable in the SK-
NEP-1 Wilms' tumor cell line and in four of five 
additional primary Wilms' tumor cases compared with 
patient-matched normal kidney (Anglesio et al., 2004).  
Zhang et al. showed that HACE1 mRNA transcripts are 
ubiquitously expressed in normal human tissues; but 
the mRNA expression of HACE1 decreases markedly 
in breast, renal, thyroid, vulva and liver tumors 
compared to the organ-matched normal tissue samples 
from the same individuals. 
The transcripts are downregulated in almost all lines 
from the NCI-60 panel of human cancer cell lines 
compared to control HEK293 cells.  
 
Schematic structure of the HACE1 protein. HACE1 contains six ankyrin repeats at the N terminus and a HECT domain at the C 
terminus. A cysteine residue essential for the ubiquitin ligase activity is at position 876. 
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Lower expression is strongly associated with 
hypermethylation of two CpG islands located upstream 
of the HACE1 locus (Zhang et al., 2007). 
HACE1 is also downregulated in natural killer/T-cell 
lymphoma of the nasal type (NKTCL) (Huang et al., 
2010), colorectal cancer (Hibi et al., 2008) and gastric 
cancer (Sakata et al., 2009). However, the expression of 
HACE1 varies in different breast cancer cell lines (Kao 
et al., 2009). In neuroblastomas, low HACE1 
expression is associated with worse overall survival, 
suggesting that HACE1 may function as a tumor 
suppressor (Diskin et al., 2012). 
Localisation 
Anglesio et al. indicated that the subcellular 
localization of HACE1 is predominantly in the 
endoplasmic reticulum (ER) and cytosol, and a small 
amount of endogenous protein is also present in other 
fractions of NIH3T3 cells (Anglesio et al., 2004). Tang 
et al. showed that a fraction of HACE1 colocalizes with 
Golgi markers in HeLa and normal rat kidney (NRK) 
cells; the association of HACE1 with Golgi membranes 
is through interaction with Golgi Rab GTPases, in 
particular Rab1 (Tang et al., 2011). 
Function 
Tumor suppressor 
Anglesio et al. showed that HACE1 possesses intrinsic 
ubiquitin ligase activity, utilizing UBCH7 as a 
candidate partner E2 enzyme (Anglesio et al., 2004). 
Zhang et al. demonstrated that HACE1 is frequently 
downregulated in human tumors and maps to a region 
of chromosome 6q21 implicated in multiple human 
cancers. Genetic inactivation of HACE1 in mice 
resulted in the development of spontaneous, late-ons t 
cancer. Their data suggested that HACE1 is involved in 
phosphorylation dependent degradation of cyclin D1,
indicating a role for HACE1 in inhibiting cell cycle 
progression (Zhang et al., 2007). 
HACE1 deficient mice are spontaneously prone to 
developing multiple malignant tumors in various 
organs (Zhang et al., 2007). 
Degradation of Rac1 
In 2011, Torrino et al. reported that HACE1 binds 
preferentially GTP-bound Rac1 and catalyzes its 
polyubiquitination. HACE1 expression increases the 
ubiquitination of Rac1 when the GTPase is activated. 
HACE1 is required for cytotoxic necrosis factor 1 
(CNSF1)-mediated depletion of Rac1 and efficient 
invasion of endothelial cell monolayer by bacteria, 
suggesting that HACE1 plays a major role in host 
defense against pathogens (Torrino et al., 2011). 
Castillo-Lluva et al. further showed that HACE1 
catalyzes polyubiquitination of Rac1 at lysine 147 
following its activation by a migration stimulus, such 
as hepatocyte growth factor (HGF), resulting in Rac1 
degradation by the proteasome. HACE1-depletion is 
accompanied by an increased total Rac1 level and 
accumulation of Rac1 in membrane ruffles. 
Furthermore, HACE1-depletion leads to enhanced cell 
migration, which may be significant for malignant 
conversion (Castillo-Lluva et al., 2012). 
Golgi biogenesis 
Tang et al. reported that HACE1 is targeted to the 
Golgi membrane through interactions with Rab 
proteins. The ubiquitin ligase activity of HACE1 in
mitotic Golgi disassembly is required for subsequent 
post-mitotic Golgi membrane fusion. Depletion of 
HACE1 using small hairpin RNAs or expression of an 
inactive HACE1 mutant protein in cells impairs post-
mitotic Golgi membrane fusion. The identification of 
HACE1 as a Golgi-localized ubiquitin ligase provides 
evidence that ubiquitin has a critical role in Golgi 
biogenesis during the cell cycle (Tang et al., 2011). 
Repression of the RAR (retinoic acid receptor)-
regulated transcription 
HACE1 was isolated as a RARβ3 AB region 
interacting protein. HACE1 functionally represses the 
transcriptional activity of RARα1 and RARβ isoforms 
1, 2 and 3, but not RARγ1 in luciferase reporter assays. 
In addition, HACE1 represses several endogenous 
RAR-regulated genes. The E3 ubiquitin ligase activity 
is not required for the repression effect of HACE1 on 
the transcriptional activity of RARβ3. HACE1 also 
inhibits the retinoic acid-dependent degradation of 
RARβ3. The repression of RAR-regulated transcription 
by HACE1 is possibly due to its ability to inhibit RA-
induced degradation of RARs (Zhao et al., 2009). 
Determinant of the equol-producing phenotype 
HACE1 was identified in a genome-wide association 
study (GWAS) designed to find genetic factors 
associated with the equol-producing phenotype in 
Korean population.  
The authors identified 5 single-nucleotide 
polymorphisms in HACE1. Individuals with a minor 
allele of the most significant SNP rs6927608 did not
produce equol.  
The interaction between equol production and the 
rs6927608 HACE1 SNP was significantly associated 
with systolic blood pressure. Finally, the authors 
concluded that equol production is linked to blood 
pressure, and HACE1 might be a determinant of the 
equol-producing phenotype (Hong et al., 2012). 
Homology 
The HACE1 gene is conserved in chimpanzee, dog, 
cow, mouse, rat, chicken, and zebrafish. 
Implicated in 
Sporadic Wilms' tumor 
Note 
In 2004, Anglesio et al. analyzed the chromosome 6q21 
breakpoint of a non-constitutional t(6;15)(q21;q21) 
rearrangement in sporadic Wilms' tumor. They showed 
that although the HACE1 locus was not directly 
interrupted by the translocation in the index Wilms' 
case, its expression was markedly lower in tumor 
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tissues compared with adjacent normal kidney. 
Moreover, HACE1 expression is virtually undetectable 
in the SK-NEP-1 Wilms' tumor cell line and in four of 
five additional primary Wilms' tumor cases compared 
with patient-matched normal kidney. Their data 
implicated that low expression of HACE1 was 
associated with sporadic Wilms' tumor (Anglesio et al., 
2004). 
In 2010, Slade et al. indentified a t(5;6)(q21;q21) 
translocation in a child with bilateral, young-onset 
Wilms' tumor. The 6q21 breakpoint transects and 
truncates HACE1, which has been implicated as a 
somatically inactivated target in Wilms tumorigenesis. 
To evaluate the contribution of HACE1 to Wilms' 
tumor predisposition, the gene was screened in 450 
individuals with Wilms' tumor. One child with 
unilateral Wilms' tumor and a truncated HACE1 
mutation was identified. It was concluded that 
constitutional disruption of HACE1 likely predisposes 
Wilms' tumor. However, HACE1 mutations are rare 
and therefore can only make a small contribution to 
Wilms' tumor incidence (Slade et al., 2010). 
Lymphoma 
Note 
HACE1 is downregulated in natural killer/T-cell 
lymphoma of the nasal type (NKTCL) in both gene 
expression profiling and array-base comparative 
genomic hybridization analyses. Since HACE1 is the 
target of epigenetic inactivation in Wilms' tumor and 
has been proposed as a tumor suppressor gene in 
multiple human cancers, it is tempting to speculate that 
HACE1 might be involved in the pathogenesis of 
NKTCL (Huang et al., 2010). 
Colorectal carcinomas and gastric 
cancer 
Note 
The methylation status of the HACE1 gene was 
examined in primary carcinomas and the corresponding 
normal tissues derived from 32 patients with colorectal 
cancer using quantitative methylation-specific PCR 
(qMSP), and the correlation between the methylation 
status and the clinic pathological findings was 
evaluated. The aberrant methylation of HACE1 was 
frequently observed in colorectal cancer. Thus HACE1 
might act as a tumor suppressor in colorectal 
carcinomas and HACE1 methylation might present a 
malignant potential in colorectal cancer (Hibi et al., 
2008). Similar research was performed in primary 
gastric carcinomas, and HACE1 was found frequently 
methylated in gastric carcinoma derived from male 
patients (Sakata et al., 2009). 
Breast cancer 
Note 
Kao et al. utilized the whole-genome DNA microarrays 
to profile gene expression and DNA copy number 
alterations (CANs) in a collection of 52 widely used 
breast cancer cell lines, and comparisons were made to 
existing profiles of primary breast tumors. The 
expression level of HACE1 varies between different 
breast cancer cell lines. The contribution of HACE1 




In a genome-wide association study of 2817 
neuroblastoma cases and 7473 controls, HACE1 and 
LIN28B were identified as two new associations at 
6q16.  
Low HACE1 and high LIN28B expression in 
diagnostic primary neuroblastomas are associated with 
worse overall survival. These data suggested that 
HACE1 might function as a tumor suppressor and 
LIN28B as an oncogene in advanced neuroblastomas 
(Diskin et al., 2012). 
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